Five-year single-centre review of ARDS patients receiving high-frequency oscillatory ventilation
© Pathmanathan et al.; licensee BioMed Central Ltd. 2014
Published: 17 March 2014
Adult ARDS patients who received HFOV from 2008 to 2012 were included. Demographics, illness severity and outcomes were collected retrospectively.
Mean APACHE II
Mean Vt (ml/kg predicted)
Vasoactive agents (%)
43.5 (day 1)
44.6 (day 1)
Hospital mortality (%)
Mortality rates were higher than in recent trials ,. Our patients represent a more critically unwell group with lower PF ratios pre HFOV and high vasoactive and RRT use. HFOV may still have a role in the treatment of these very sick patients with treatment refractory to conventional ventilation.
This article is published under license to BioMed Central Ltd. This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2014 and co-published as a series in Critical Care. Other articles in the series can be found online at http://ccforum.com/series/annualupdate2014. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901.